Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in Working CapitalChange in Working CapitalExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Free Cash Flow (2019 - 2025)

Innate Pharma posted quarterly Free Cash Flow of -$61.2 million for Q4 2025, down 781.09% year-on-year from $9.0 million in Q4 2024, and down 781.09% on a QoQ basis from -$7.0 million in Q4 2024.

Innate Pharma (IPHA) has 7 years of Free Cash Flow data on file, last reported at -$61.2 million in Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 781.09% year-over-year to -$61.2 million; the trailing twelve-month figure through Dec 2025 stood at -$68.2 million (down 26.87% YoY), and the FY2025 full-year result was -$61.4 million, down 688.63% from the prior year.
  • Free Cash Flow for Q4 2025 stood at -$61.2 million, down from -$7.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $448163.8 in Q2 2022 and bottomed at -$65.8 million in Q4 2021.
  • The 5-year median for Free Cash Flow is -$26.8 million (2023), against an average of -$29.6 million.
  • The widest annual swing landed in 2022, when Free Cash Flow soared 101.2%; it then sank 2810.63% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$65.8 million in 2021, then soared by 71.13% to -$19.0 million in 2022, then tumbled by 82.42% to -$34.7 million in 2023, then jumped by 79.94% to -$7.0 million in 2024, then tumbled by 781.09% to -$61.2 million in 2025.
  • The last three Free Cash Flow figures came in at -$61.2 million (Q4 2025), -$7.0 million (Q4 2024), and -$34.7 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Free Cash Flow (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -1.67 Mn
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -12.20 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -2.49 Mn
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn 1.29 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn 848.30 Mn
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn 48.67 Mn
10 Innate Pharma 199.64 Mn 199.64 Mn - -61.25 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -61.25 Mn
Dec 31, 2025 -61.25 Mn
Dec 31, 2024 -6.95 Mn
Dec 31, 2024 -6.95 Mn
Dec 31, 2023 -34.65 Mn
Dec 31, 2023 -34.65 Mn
Jun 30, 2023 -12.15 Mn
Jun 30, 2023 -12.15 Mn
Dec 31, 2022 -19.00 Mn
Dec 31, 2022 -19.00 Mn
Jun 30, 2022 448,163.81
Jun 30, 2022 448,163.81
Dec 31, 2021 -65.81 Mn
Dec 31, 2021 -65.81 Mn
Jun 30, 2021 -37.24 Mn
Jun 30, 2021 -37.24 Mn
Dec 31, 2020 -60.64 Mn
Dec 31, 2020 -60.64 Mn
Jun 30, 2020 -63.31 Mn
Jun 30, 2020 -63.31 Mn
Dec 31, 2019 1.41 Mn
Dec 31, 2019 1.41 Mn
Jun 30, 2019 829,245.65
Jun 30, 2019 829,245.65